SCHEMBL2180140

SCHEMBL2180140

BrCCCC#Cc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
THPO P40225 1/20 0.50
BLM P54132 1/20 0.48
PMP22 Q01453 1/20 0.48
APP P05067 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
HTR2A P28223 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
TSHR P16473 1/20 0.39
CHRNA7 P36544 2/20 0.39
CHRNA10 Q9GZZ6 2/20 0.39
CHRNA9 Q9UGM1 2/20 0.39
FFAR1 O14842 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8522596 0.92 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C9CYP2C19THPO
SCHEMBL8590492 0.92 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C9CYP2C19THPO
SCHEMBL3348718 0.88 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C9CYP2C19THPO
SCHEMBL17534680 0.86 CYP1A2 (0.54) CYP1A2CYP3A4CYP2C9CYP2C19THPO
SCHEMBL17911731 0.86 CYP1A2 (0.58) CYP1A2CYP3A4CYP2C9CYP2C19THPO
SCHEMBL2179678 0.85 HTR2C (0.38) CYP1A2CYP3A4CYP2C9CYP2C19THPO
SCHEMBL10768214 0.81 CYP1A2 (0.64) CYP1A2CYP3A4CYP2C9CYP2C19THPO
SCHEMBL2175823 0.80 CYP3A4 (0.47) CYP1A2CYP3A4CYP2C9CYP2C19HRH3
SCHEMBL1878352 0.79 CHRNA7 (0.39) CHRNA7CHRNA10CHRNA9
SCHEMBL1315019 0.79 APP (0.50) APPMAPTFFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10071982-B2 Method of treating neuropathic pain UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2018-09-11 US disclosed
US-20160340335-A9 METHOD OF TREATING NEUROPATHIC PAIN UNIVERSITY OF UTAH (US) 2016-11-24 US disclosed
US-9499518-B2 Bis-quaternary ammonium salts as pain modulating agents UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2016-11-22 US disclosed
US-20160279119-A9 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2016-09-29 US disclosed
US-8981118-B2 Process for the preparation of benzodithiophene compounds ENI S.P.A. (IT) 2015-03-17 US disclosed
US-20140364628-A1 PROCESS FOR THE PREPARATION OF BENZODITHIOPHENE COMPOUNDS ENI S.P.A. (IT) 2014-12-11 US disclosed
US-8853425-B2 Process for the preparation of benzodithiophene compounds ENI S.P.A. (IT) 2014-10-07 US disclosed
US-20140235874-A1 PROCESS FOR THE PREPARATION OF BENZODITHIOPHENE COMPOUNDS ENI S.P.A (IT) 2014-08-21 US disclosed
US-20140155631-A1 PROCESS FOR THE PREPARATION OF BENZODITHIOPHENE COMPOUNDS ENI S.P.A. (IT) 2014-06-05 US disclosed
US-20140011836-A1 METHOD OF TREATING NEUROPATHIC PAIN UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2014-01-09 US disclosed
US-20110166177-A1 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2011-07-07 US disclosed
WO-2007149163-A2 BIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS UNIVERSITY OF KENTUCKY (US) 2007-12-27 WO disclosed
WO-2007149163-A2 BIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS UNIVERSITY OF KENTUCKY (US) 2007-12-27 WO disclosed
WO-2007076112-A2 TRIS-QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS UNIVERSITY OF KENTUCKY (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166177-A1 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS RELA, FHIT, OPRL1 CYP1A2 4692/4885CYP3A4 4540/4885CYP2C9 4538/4885
US-10071982-B2 Method of treating neuropathic pain INA, GAP43, ACHE CYP1A2 4459/4885CYP3A4 4701/4885CYP2C9 4529/4885
US-20160340335-A9 METHOD OF TREATING NEUROPATHIC PAIN INA, GAP43, ACHE CYP1A2 4459/4885CYP3A4 4701/4885CYP2C9 4529/4885
US-20140155631-A1 PROCESS FOR THE PREPARATION OF BENZODITHIOPHENE COMPOUNDS DDC, DDT, AOC1 CYP1A2 1723/4885CYP3A4 1438/4885CYP2C9 1682/4885
US-20140364628-A1 PROCESS FOR THE PREPARATION OF BENZODITHIOPHENE COMPOUNDS DDC, DLST, HLCS CYP1A2 1441/4885CYP3A4 541/4885CYP2C9 1105/4885
US-20160279119-A9 BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS RELA, FHIT, OPRL1 CYP1A2 4692/4885CYP3A4 4540/4885CYP2C9 4538/4885
US-20140011836-A1 METHOD OF TREATING NEUROPATHIC PAIN INA, GAP43, ACHE CYP1A2 4459/4885CYP3A4 4701/4885CYP2C9 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.